Evidence map›Paper›PMID 29124624›Full record

ArticleMaternal and child health journal2018

Maternal Hypertension, Antihypertensive Medication Use, and Small for Gestational Age Births in the National Birth Defects Prevention Study, 1997-2011.

Sarah C Fisher, Alissa R Van Zutphen, Paul A Romitti, Marilyn L Browne, National Birth Defects Prevention Study

Open access · greenAbstract read
In one paragraph

Article in Maternal and child health journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sarah C FisherCongenital Malformations Registry, New York State Department of Health, Albany, NY, USA. sarah.fisher@health.ny.gov.
Alissa R Van ZutphenCongenital Malformations Registry, New York State Department of Health, Albany, NY, USA.
Paul A RomittiDepartment of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, USA.
Marilyn L BrowneCongenital Malformations Registry, New York State Department of Health, Albany, NY, USA.
National Birth Defects Prevention Study
New York State Department of Health · USUniversity of Iowa · US

Funding

Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Jong Sung Kim · 1990 to 2026
$40.5M
Iowa Center for Birth Defects Research and Prevention (ICBDRP)U01DD000492 · DD · UNIVERSITY OF IOWA · PI ROMITTI, PAUL A · 2009 to 2013
$3.9M
Iowa CBDRP: Birth Defects Study To Evaluate Pregnancy exposureSU01DD001035 · DD · UNIVERSITY OF IOWA · PI ROMITTI, PAUL A · 2013 to 2017
$3.5M
ACL HHS U01DD001032CDC HHS Cooperative Agreement U01DD001032NCBDD CDC HHS U01 DD000492NCBDD CDC HHS U01 DD001032NCBDD CDC HHS U01 DD001035NIEHS NIH HHS P30 ES005605
6 · The paper itself

Abstract

Background Small for gestational age (SGA) birth is associated with poor long-term health outcomes. It is unclear whether maternal antihypertensive medication increases risk of SGA independently of maternal hypertension. Methods We analyzed associations between maternal hypertension and antihypertensive medication use and SGA among non-malformed singleton controls in the National Birth Defects Prevention Study. We defined SGA as birthweight < 10th percentile for a given gestational age, sex, race/ethnicity, and parity. We included 1045 SGA and 10,019 non-SGA births. We used logistic regression to calculate adjusted odds ratios (AORs) and 95% confidence intervals (CIs). We assessed interaction between hypertension, antihypertensive use, and maternal race/ethnicity and age. Results Overall, 122 (11.7%) SGA and 892 (8.9%) non-SGA mothers reported hypertension and 21 (2.0%) SGA and 154 (1.5%) non-SGA mothers reported antihypertensive use. The most commonly reported medications were centrally-acting antiadrenergics, β-blockers, calcium channel blockers, and diuretics. Compared to normotensive pregnancies, maternal hypertension, regardless of treatment (AOR, 1.49 [95% CI, 1.20, 1.86]), and untreated maternal hypertension [AOR, 1.46 (95% CI, 1.15, 1.86)] were associated with SGA. We observed a positive, but not significant, association between antihypertensive use and SGA. SGA risk varied by maternal race/ethnicity, being highest among Hispanic mothers, and age, being highest among mothers ≥ 35 years, but statistical tests for interaction were not significant. Conclusions Consistent with the literature, our findings suggest that maternal hypertension slightly increases SGA risk. We did not observe an appreciably increased SGA risk associated with antihypertensive medication use beyond that of the underlying maternal hypertension.

Indexed as

Infant, Small for Gestational AgeMaternal AgeMothersAdultAntihypertensive AgentsCase-Control StudiesFemaleGestational AgeHumansHypertensionHypertension, Pregnancy-InducedInfant, NewbornPre-EclampsiaPregnancyPregnancy OutcomeRetrospective StudiesAntihypertensive AgentsAntihypertensive medicationHypertensionNational Birth Defects Prevention StudyPregnancySmall for gestational age

Identifiers

PMID29124624
PMCPMC10068427
OpenAlexW2767818231

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.